Effects of Hydroxytyrosol-Rich Olive Polyphenol Dietary Supplement Combined With Mediterranean Diet Adherence on the Cognitive Health of Patients With Mild Cognitive Impairment (MEDIPHENO-HT)
28. Juni 2026 aktualisiert von: Panhellenic Federation of Alzheimer's Disease and Related Disorders
Hydroxytyrosol-Rich Olive Juice Polyphenol and Mediterranean Diet (The MEDIPHENO-HTrial) in Prevention of Cognitive Decline in Community-Dwelling Patients With Mild Cognitive Impairment: A Double-Blind, Placebo-Controlled, 3-Arm, Randomised Controlled Clinical Study
Nutrition is an important modifiable risk factor of human cognitive health.
Increasing data suggests that certain nutrients or food ingredients, such as plant polyphenols, have the potential to benefit cognitive abilities even in later life.
In terms of polyphenols, Hydroxytyrosol (HT) has gained health benefit claims as a potential preventative antioxidant supplementation of neurodegenerative and amyloid-associated diseases while its pharmacological mechanisms suggest protection against cognitive decline.
The primary objective of this study will be to evaluate the effects of HT-rich olive juice polyphenol supplementation alongside MeDi adherence compared with placebo alongside MeDi adherence in the prevention of cognitive decline among patients with Mild Cognitive Impairment associated with AD and non-AD pathology.
Studienübersicht
Status
Rekrutierung
Bedingungen
Studientyp
Interventionell
Einschreibung (Geschätzt)
141
Phase
- Unzutreffend
Kontakte und Standorte
Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.
Studienkontakt
- Name: Magda Tsolaki, Professor Emeritus, MD, PhD
- Telefonnummer: +30 2310316143
- E-Mail: tsolakim1@gmail.com
Studienorte
-
-
Central Macedonia
-
Thessaloniki, Central Macedonia, Griechenland, 54250
- Rekrutierung
- Palliative Care Centre "Panagia Glykofilousa", Greek Association of Alzheimer's Disease and Related Disorders, Plastira 65, Thessaloniki 54250, Greece.
-
Kontakt:
- Magda Tsolaki, Professor Emeritus, MD, PhD
- Telefonnummer: +30 2310316143
- E-Mail: tsolakim1@gmail.com
-
-
Teilnahmekriterien
Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.
Zulassungskriterien
Studienberechtigtes Alter
- Erwachsene
- Älterer Erwachsener
Akzeptiert gesunde Freiwillige
Nein
Beschreibung
Inclusion Criteria:
- GR-based men and women aged 50 - 85
- Willingness and ability to conform to the full protocol.
- Ability to accept and sign the consent form.
- Presence of a diagnostic classification of Mild Cognitive Impairment according to the National Institute on Aging and Alzheimer's Association (NIA-AA) framework MCI, which corresponds to stage 3 on the pre-dementia range.
- MoCA score of ≥18 and ≤ 26. Or
- MMSE (Mini-Mental State Examination) score of ≥26 and ≤ 28.
- No active suicide ideation based on the Columbia-Suicide Severity Rating Scale.
- Absence of severe depressive symptomatology based on the Geriatric Depression Scale-15.
- Not using any laxative drugs for at least three days prior to the screening visit.
- Information about APOE status
Exclusion Criteria:
- Patients with mild, moderate, or severe dementia.
- Current or recent (within the last 4 weeks) engagement with a strict dietary regime i.e., vegetarian / vegan / ketogenic / paleolithic / high protein / weight loss.
- Any known issues with blood taking.
- Any known bleeding disorders.
- Any known allergy to olives, inability to tolerate gluten or multiple allergies/intolerances that would significantly limit food intake.
- Average alcohol use of >21 glasses per week for men and >14 glasses per week for women (on average for the last six months).
- History of psychiatric illness including intellectual disability, schizophrenia, bipolar disorder, severe, active depression and alcoholism.
- Neurologic conditions such as vascular dementia, movement disorders, history of conditions such as anaemia and cancer in the last five years, renal or liver failure, malignant tumours, or organ transplant.
- Coffee consumption greater than 5 cups per day.
- Body mass index > 35 kg/ m2.
- Not taking a stable dose of statins for at least 3 months before the recruitment visit. Taking antibiotics in the 1 week preceding the recruitment visit.
- Pregnancy or lactation.
- Participation in another clinical trial during the last 30 days prior to the recruitment visit.
- Subject taking supplements that may affect lipoprotein metabolism, >1 g of fish oil/day, antioxidant supplements, cannabidiol (CBD) oil.
Studienplan
Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Verhütung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Verdreifachen
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
|---|---|
|
Aktiver Komparator: Active Arm - Low Dose
Low dose: 8 drops (20mg of polyphenols) + Mediterranean Diet instructions
|
This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial.
The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies.
Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo.
The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.
|
|
Experimental: Experimental Arm - High Dose
High dose: 16 drops (40mg of polyphenols) + Mediterranean Diet instructions
|
This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial.
The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies.
Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo.
The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.
|
|
Placebo-Komparator: Placebo Comparator Arm
Placebo 8 drops + Mediterranean Diet instructions
|
This is a prospective, randomised, double-blind, three-arm, placebo-controlled with 1:1:1 randomisation and 52-week follow-up trial.
The MEDIPHENO-HTrial study will enrol patients within the Mild Cognitive Impairment spectrum related to AD and non-AD type pathologies.
Participants will be randomised to receive either 8 drops of the active HT-high phenolic supplement, or 16 drops of the active HT-high phenolic supplement or 8 drops of the matching placebo.
The Mediterranean diet adherence support will be delivered identically to all groups to reduce dietary confounding.
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Primary: Mean change on the Alzheimer's Disease (AD) Assessment Scale-Cognitive Subscale (ADAS-Cog) total score from baseline to Week 52 compared with placebo
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the cognitive performance of patients with MCI as measured by ADAS-Cog.
ADAS-Cog ranges from 0-85 by summing the number of errors made on each task, so that higher scores indicate worse performance.
|
From baseline to Week 52
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Key secondary: Mean change on the Montreal Cognitive Assessment Test (MoCA) total score from baseline to Week 52 compared with placebo
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the cognitive performance of patients with MCI as measured by MoCA.
The total possible score for the test is 30 points by summing the number of correct responses given in each task, so higher scores indicate better performance.
|
From baseline to Week 52
|
|
- Mean change on Clinical Dementia Rating - Sum of boxes (CDR-SB) from baseline to Week 52 compared with placebo
Zeitfenster: From baseline to Week 52
|
- The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the CDR-SB, which ranges from 0 to 18, and is calculated by summing the ratings across each of the six domains (memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care), with higher scores indicating greater impairment.
|
From baseline to Week 52
|
|
Mean change on Mini-Mental State Examination (MMSE) from baseline to Week 52 compared with placebo
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on the MMSE, which is a 30-point brief screening measure of cognitive status.
Higher scores indicate better performance.
|
From baseline to Week 52
|
|
- Mean change on Geriatric Depression Scale-15 (GDS-15) from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
- The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on GDS-15, which consists of 15 items and is used to screen for depression in adults.
GDS-15 assess mental health based on feelings over the past week, with higher scores on the measure denoting more severe levels of depressive symptoms.
|
From baseline to Week 52
|
|
- Mean change on Short Anxiety Screening Test (SAST-10) from baseline to Week 52 compared with placebo
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on SAST-10, which is a brief questionnaire designed to assess anxiety.
SAST-10 scores range from 10 to 40, with higher scores on the measure denoting more severe levels of anxiety symptoms.
|
From baseline to Week 52
|
|
- Mean change on Functional Rating Scale of Symptoms of Dementia (FRSSD) from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on FRSSD.
The scale ranges from 0 (fully independent) to 42 (fully dependent), with lower scores indicating better daily functioning.
|
From baseline to Week 52
|
|
- Mean change on Alzheimer's Disease Cooperative Study - Activities of Daily Living Scale for use in Mild Cognitive Impairment (ADCS-MCI-ADL) from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52.
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on ADCS-MCI-ADL, which is a brief questionnaire designed to capture functional abilities (with recall "In the past 4 weeks").
The 18-item ADCS-ADL-MCI is scored from 0 to 53 based on the subject's degree of independence in performing specific tasks.
Lower scores on the measure denote more substantial impairment.
|
From baseline to Week 52.
|
|
- Mean change on Quality of life in Alzheimer's disease (QoL-AD) from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52.
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on QoL-AD, which is a brief 13-item questionnaire designed to assess quality of life.
QoL-AD range from 13 to 52, with higher scores indicating better quality of life.
|
From baseline to Week 52.
|
|
- Mean change on - Pittsburgh Sleep Quality Index (PSQI) from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52.
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on PSQI, which is a questionnaire designed to assess Sleep quality.
PSQI range from 0 to 21, with higher scores indicating poor sleep.
|
From baseline to Week 52.
|
|
- Mean change in LDL-C mg/dL cholesterol from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on LDL-C mg/dL cholesterol.
|
From baseline to Week 52
|
|
- Mean change in HDL-C mg/dL cholesterol from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
The effects of Hydroxytyrosol-Rich Olive Juice Polyphenol Supplement compared with placebo on HDL-C mg/dL cholesterol.
|
From baseline to Week 52
|
Andere Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Mean percentage change in plasma phosphorylated tau 217 (p-tau217) pg/mL from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
Exploratory analyses will include blood biomarkers, p-tau217 pg/mL.
Mean percentage change in plasma p-tau217 pg/mL from baseline to Week 52 compared with placebo.
|
From baseline to Week 52
|
|
Mean percentage change in plasma levels of beta-amyloid 1-42 (Aβ 1-42) pg/mL from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
Exploratory analyses will include blood biomarkers, Aβ 1-42 pg/mL.
Mean percentage change in plasma levels of Aβ 1-42 pg/mL from baseline to Week 52 compared with placebo.
|
From baseline to Week 52
|
|
Mean percentage change in plasma Glial Fibrillary Acidic Protein (GFAP) pg/mL concentration from baseline to Week 52 compared with placebo.
Zeitfenster: From baseline to Week 52
|
Exploratory analyses will include blood biomarkers, GFAP pg/mL.
Mean percentage change in plasma GFAP pg/mL concentration from baseline to Week 52 compared with placebo.
|
From baseline to Week 52
|
Mitarbeiter und Ermittler
Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.
Mitarbeiter
Ermittler
- Hauptermittler: Vilma Chalili, School of Medicine, Aristotle University of Thessaloniki
- Studienstuhl: Magda Tsolaki, First Department of Neurology, Faculty of Health Sciences, School of Medicine, Aristotle University of Thessaloniki
Studienaufzeichnungsdaten
Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.
Haupttermine studieren
Studienbeginn (Tatsächlich)
31. März 2025
Primärer Abschluss (Geschätzt)
1. Dezember 2026
Studienabschluss (Geschätzt)
1. Dezember 2026
Studienanmeldedaten
Zuerst eingereicht
17. Juni 2026
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
22. Juni 2026
Zuerst gepostet (Tatsächlich)
29. Juni 2026
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
30. Juni 2026
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
28. Juni 2026
Zuletzt verifiziert
1. Juni 2026
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
- 107/12-3-2025
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
NEIN
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Nein
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Nein
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .